Research Consortium, Testing Service Hope to Turn Cancer Genome Analyses into Rx Selections

According to CollabRx’s CEO Marty Tenenbaum, the project serves a dual purpose: generating research results and funneling them back to study participants. “You can really think about this as personalized research, but also aggregating the results to drive the field,” he said.

Both the project and the service are designed to offer cancer patients detailed information about their tumor at a timescale that can help their physicians tailor treatments.

Connect With Us
Join other physicians who are receiving our updates.
We hate spam. Your email address will not be sold or shared with anyone else.